Home » Business, Education, Food & Beverage, Health & Medicine, News & Current Affairs » New Hope For PTSD And ADHD Sufferers Experiencing Terrifying Nightmares

New research recently published by Dr. Kenneth Blum, co-discoverer of the reward gene (DRD2-A1) – a.k.a. the addiction gene, and the alcoholic gene – Dr. Thomas McLauglin and other noted doctors, scientists and researchers in the peer review open access journal Reward Deficiency Syndrome & Addiction Science suggests that an alternate form of treatment for lucid dreams experienced by PTSD and ADHD suffers may be on the horizon.

According to Dr. Blum, “It is not unusual for a remedy to be found as an effective therapy for an ailment other than its intended target.” Such was the case for Thomas McLauglin MD, PhD from the Center for Psychiatric Medicine, North Andover,, Massachusetts, who was treating addicts suffering from PTSD with an innovative nutraceutical proven to balance brain chemistry. McLauglin found that this all natural nutraceutical mitigated and even eliminated terrifying lucid dreams experienced by his PTSD and ADHD patients.

PTSD is more perverse than most people realize. About 3.6 percent of U.S. adults aged 18 to 54 (5.2 million people) have PTSD during the course of a given year. According to the U.S. Department of Veterans Affairs who tracks PTSD research, 71% to 96% of the people suffering from PTSD may have threatening and/or scary nightmares. Other studies are reporting up to 80%, of those with PTSD, experience nightmares that have them reliving or re-experiencing the traumatic event for months or years after the actual event took place.

Additionally, nightmare disorder affects 11 percent of children with ADHD and lifetime nightmare disorder affects 23 percent, versus 5 and 16 percent of controls. ADHD is diagnosed approximately three times more in boys than in girls. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood. Between 2–5% of adults have the condition.

The pilot study led by Dr. McLaughlin along with nine other qualified authors representing a number of psychiatry departments in prestigious Universities, provided clear evidence that a well-researched Pro-dopamine regulator KB220Z (Synaptamine™) alleviated terrifying lucid dreams in four patients studied.

Previously, the same group published two peer reviewed articles showing complete elimination of these nightmares. Now a total of thirteen of their patients show this dramatic effect translating to a 92% success rate. However, the most exciting finding to date is that in the current case study the authors have surprisingly found a one-year protracted elimination of these lifelong lucid-nightmares up to one –year after stopping KB220z. The authors raise the question of the possibility of neuroplasticity (the brain’s ability to reorganize itself by forming new neural connections throughout life) induced changes in the brain-reward circuitry.

To help answer this important but perplexing question, Marcelo Febo, PhD Assistant Professor of the department of Psychiatry, University of Florida School of Medicine, utilized acute fMRI experiments in naïve rodents. It was then revealed that compared to placebo, KB220Z (at an equivalent human dose) resulted in an increased connectivity volume (increased recruitment of neurons firing) in brain regions associated with lucid dreams.  Certainly, rodent experiments do not tell us anything about human dreaming but may help us understand in-part the possibility of central nervous system neuro-adaptations.

Dr. Blum acknowledges the small sample size but then quoted the famous 19th century French physiologist, Claude Bernard; “Science does not permit exceptions.” He also stated; “I could have never imagined KB220Z would be so effective at eliminating lucid nightmares in PTSD/ADHD suffers,” and vowed to continue his research into the subject.

You can find the entire research paper titled: KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams here: http://blumsrewarddeficiencysyndrome.com/ets/articles/v1n1/jrdsas-021-thomas-mclaughlin.pdf

For more information on KB220Z/Synaptamine™ please visit: http://www.talkrds.com/

Doctor Blum is available for interviews on a limited basis. To book an interview or for more information please contact:

Joe Ullrich
Omni Publicity And Public Relations Group
http://www.omnipublicity.com

CREDENTIALS: Kenneth Blum, B.Sc. (Pharmacy), M.Sc., Ph.D. & DHL; received his Ph.D. in Neuropharmacology from New York Medical College and graduated from Columbia University and New Jersey College of Medicine. He also received a doctor of humane letters from Saint Martin’s University Lacey, WA. He has published more than 550 abstracts; peer-reviewed articles and 14-books. Dr. Blum has been the recipient of many NIH grants and numerous awards including the prestigious Life-Time Achievement in Addiction Medicine from The Holistic Institute of Addiction Studies and The Presidential Award for Scientific Excellence from National Council of Alcohol & Drug Abuse Councilors. Blum is the Editor in Chief of “Addiction Genetics.”  Currently, Dr. Blum is serving as Editor-In-Chief of “Journal of Reward Deficiency Syndrome” and co-Editor-In-Chief of “Journal of Neuroimaging in Psychiatry and Neurology” and is on 7 prestigious journal editorial boards. Prof. Blum is also a founder President of USG and founder President of USG Editors Association (USGEA). Dr. Blum is the recipient of Julius Axelrod (Nobel Laureate) Distinguished Speaker Award.

Media Contact
Company Name: Omni Publicity
Contact Person: Joe Ullrich
Email: Joe@omnipublicity.com
Phone: 813-944-3024
City: San Francisco
State: California
Country: United States
Website: http://www.omnipublicity.com

Comments are closed.